Search is Powered by Google
Cancer / Oncology News

The European CanCer Organisation Welcomes The European Parliament's Vote To Postpone Implementation Of The EU Directive On Electromagnetic Fields

Main Category: Cancer / Oncology
Also Included In: MRI / PET / Ultrasound;  Radiology / Nuclear Medicine
Article Date: 22 Feb 2008 - 1:00 PDT

email icon email to a friend   printer icon printer friendly   write icon view / write opinions   rate icon rate article
Current Article Ratings:

Patient / Public:not yet rated

Health Professional:not yet rated

Article Opinions: 0 posts

ECCO - the European CanCer Organisation - has welcomed the European Parliament's overwhelming vote to postpone for four years the implementation of the EU Directive on electromagnetic fields.

The EU Physical Agents (Electromagnetic Fields) Directive 2004/40/EC was due to be implemented in all member states by April this year, but it would have had the unintended effect of halting the use of magnetic resonance imaging (MRI), an important tool in cancer diagnosis, treatment and research. On February 19 (2008), the European Parliament voted to postpone the Directive until 2012 in order to allow time for extensive consultation and amendment to take place.

Professor Alexander Eggermont, President of ECCO, said: "We are delighted that the European Parliament has voted to postpone the implementation of this EU Directive. ECCO represents some 40,000 professionals working across Europe and we were most concerned that the Directive would have effectively banned the use of MRI for cancer diagnosis and cancer research. This would have been very bad news for patients as some eight million MRI patient examinations are carried out each year in Europe.

"The Directive would have posed particular problems to those healthcare staff that care for patients such as children, the elderly, or those who have been anaesthetised, and who need help and comfort during scans. It would also have stopped the use of MRI for interventional and surgical procedures.

"ECCO will now be involved in the scientific consultations that the European Commission will be undertaking to amend the Directive, in order to ensure that major advances that have been made in cancer care are not put into jeopardy."

The European CanCer Organisation




Customized Homepage Weekly Newsletters Daily News Alerts
Home About Us News Licensing Free Website Feeds Free Tools & Content Links Tell a Friend Accessibility Help / FAQ Article Submission Contact Us
Psychiatry Urology
Bipolar Diabetes Schizophrenia

add medical news today to your facebook

medical news gadget

Add to Google


developers
website gadget code
website news code
medical news rss feed links


MedReader RSS Reader

customize your homepage


These are the most read articles from this news category for the last 6 months:
Top Article Star
Shocking Pictures To Appear On Cigarette Packets In UK On 1st October
27 Sep 2008
The UK's ten million Smokers may see pictures of rotting teeth, throat cancer, and indications of male impotence (erectile dysfunction) on cigarette packets they buy at the beginning of October...


Monitoring and Adherence in CML image Monitoring and Adherence in CML

Imatinib, or Gleevec, is a targeted anti-cancer drug that can keep chronic myelogenous leukemia (CML) in check for most patients for many years. It is important for patients to take imatinib as prescribed by their doctor to fight the disease and to guard against resistance...

Treating HER2+ Breast Cancer image Treating HER2+ Breast Cancer

There are at least four different kinds of breast cancer and each is treated differently. For HER2+ breast cancer, a chemotherapy drug is typically the best option. Here's an overview of the drugs used to treat breast cancer...

View more videos...